← Russell 3000 cross-section

UPB Upstream Bio, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-11, not restated
Healthcare

Scale

Market cap
$376m
Revenue TTM
$3m
Net income TTM
$-156m
Free cash flow
Composite score
Sector rank
#2538

Valuation

P / E
EV / EBITDA
EV / sales
36.3
FCF yield
Earnings yield vs 10-yr
-46.35pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-4,955.7%
EBITDA margin
-5,376.2%
ROE
-57.8%
ROIC
-1,761.5%
Revenue growth

Insider activity, last 90 days

Net open-market
$-0.03m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In connection with the ATM Program, we filed the ATM Prospectus on March 26, 2026 for the offer and sale of up to $150.0 million of shares of common stock from time to time through the sales agent.Upstream Bio, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-11

Read the full passage →